DOCSLIB.ORG

Jenner Vaccine Foundation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jenner Vaccine Foundation Institute for Animal Health Jenner Vaccine Foundation Issue 01 | November 2009 News HigHligHts New tB vaccine begins Phase llb trials in south Africa £100m iAH development at Pirbright Bill gates visits the Jenner institute laboratories Current challenges in HiV vaccine research Institute of Animal Health 1 1 Welcome to the first edition of the Jenner Vaccine Foundation From the Newsletter. National Chairman the Jenner Vaccine Foundation was established as a charitable organisation in 2005 as a partnership between the Institute for Animal institute Health and the University of Oxford to foster parallel development for Health of vaccines for human and veterinary use. During its first few years, the primary activity of the Foundation has been the provision of support Research to scientists working on vaccine development at the two sponsor organisations who constitute the Jenner institute. This support has £1.8m Award included a financial contribution to the cost of a new laboratory building on the Churchill Road campus, which now hosts many of the scientists The Clinical Biomanufacturing working on vaccines at the University of Oxford, some limited financial Facility (CBF), a Jenner Institute unit which provides the key support for 24 distinguished scientists working on vaccine development interface between research at the two sponsor organisations – the Jenner investigators – and and clinical medicine and Brian Greenwood sponsoring seminars and workshops. The Foundation now seeks to manufactures Investigational expand its activities to include training and advocacy as well as support for research. A fundraising Medicinal Products (IMPs) to programme will be launched shortly to support these expanded roles and an effective newsletter GMP standards for first in human could facilitate these goals. clinical trials, has been awarded The Jenner Vaccine Foundation newsletter has two main purposes. Firstly, it seeks to advertise a £1.8 million grant from the to a general audience some of the exciting research on vaccine development being undertaken by NIHR (National Institute for scientists at the two sponsor organisations. Secondly, it provides a forum for members of the Jenner Health Research). The grant will Institute to express their views on what they see as key features related to the objectives of the be used to increase the capacity Foundation and on vaccine research more broadly. of the CBF to produce vaccines for translational research within Newsletters such as this one work only if their readers find them interesting and are prepared to the Jenner Institute while contribute. Please contribute and help to make this a lively forum. also strengthening the BRC’s partnership with the NHS, Oxford Radcliffe Hospital Trust and University of Oxford. New tB Vaccine Begins Phase llb trials Specifically, the grant will improve the unit’s infrastructure The new TB vaccine, MVA85A, developed by Jenner Investigator Dr Helen McShane has by providing additional clean commenced Phase IIb trials in Worcester, South Africa. This is the first efficacy trial of room space allowing for more a new TB vaccine in more than 80 years. flexible functionality, a filler unit and a semi-automatic fill line. TB infects around 2 billion people worldwide making MVA85A the first of the new generation of The Head of CBF, Sarah (almost a third of the population) and is one of the TB vaccines to enter into a proof-of-concept trial. Moyle, commented on the grant: world’s biggest killers causing around 1,8 million This trial will involve around 2,800 BCG-vaccinated “Despite a strong record of deaths per year, with South Africa being one of the infants, half of whom will receive MVA85A and several types of products for first most affected countries. The current vaccine (BCG) half of whom will receive a placebo. The infants in human trials, the CBF has been is given throughout the developing world and parts will then be followed up for two years to monitor unable to meet all the clinical of the developed world. BCG works well to prevent rates of TB in both groups, as well as safety and needs for GMP manufacture of disease in infants but is not very effective in adults, immunogenicity. Previous trials in the UK, South cutting edge biologicals due to especially against lung disease, which is the major Africa and The Gambia have already shown that lack of suitable manufacturing cause of disease burden; therefore, MVA85A is MVA85A is safe and that it induces the type of space. This grant will enable my designed to enhance the immune response to BCG. immune response that is thought to be protective team to increase the output of The Phase IIb trial in South Africa started against TB. The results of this study should be cost-effective therapeutic and earlier this year at the South African TB Vaccine available in 2012. prophylactic vaccines which Initiative (SATVI) site at Brewelskloof Hospital The trial is jointly funded by the Wellcome Trust are being developed by leading in Worcester, around 100 km from Cape Town, and the Aeras Global TB Vaccine Foundation. The Oxford clinical and academic money from the Wellcome Trust is in the form of a collaborators. It will also allow Strategic Award to Dr McShane, based at the Jenner us to extend our services to cover Laboratories at the University of Oxford, and OETC other biological materials in (Oxford-Emergent Tuberculosis Consortium Ltd.). addition to viruses; it is essential The trial is being run in collaboration with OETC, that we remain as flexibly SATVI and AERAS, who will be the trial sponsor. functional as possible to meet the needs of our users.” She continued: “These funds could Worcester, Cape Town, July 2009 - Four-month old not have come at a better time; Janenique Pienaar of Worcester, South Africa, made history this grant will ensure that we will on Wednesday 15 July 2009 when she became the first baby be able to increase capacity and in 80 years to be vaccinated in a proof of concept efficacy trial (Phase IIb) of a candidate TB vaccine. The candidate manufacture multiple products vaccine, MVA85A/Aeras-485, is being tested at the TB in parallel, whilst meeting the vaccine research site of the South African Tuberculosis stringent regulatory demands Vaccine Initiative (SATVI) of the University of Cape Town, in these novel cutting-edge partnership with Aeras Global TB Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd. and the products require”. Wellcome Trust. 2 the new institute for Animal Health Re-development at Pirbright The Institute for Animal Health (IAH) Pirbright Laboratory is a world-leader in Professor Martin shirley, research into exotic virus diseases of animals, iAH’s Director: especially cattle, sheep and pigs. As part of its national and international role, IAH- “I am absolutely delighted by the Pirbright currently houses the FAO World news; it is a clear vote of confidence Reference Laboratory for foot and mouth in the world-class science carried disease (FMD) and the World Reference out at IAH and recognises the Laboratory for Morbilliviruses; the EU increasing threats posed by animal Community Reference Laboratories for FMD, diseases such as foot and mouth, swine vesicular disease and bluetongue; and bluetongue, and African swine acts as World Organisation for Animal Health fever, which could cause massive (OIE) Reference/Regional laboratories for IAH Common Area economic and social damage. eight of the major exotic diseases of livestock The investment in state-of-the-art which threaten the UK livestock industry. isolation unit and new site infrastructure. These laboratories provide essential national Following the 2007 FMD outbreak in Surrey, facilities at IAH will ensure the UK is and global diagnostic services and are in the progress stalled but on July 27 2009, Treasury in a position to control, contain and front-line for handling emergency outbreaks of approved £100m funding for a new state-of- eradicate the threats of established several major exotic viral diseases of livestock. the art laboratory that will deliver an excellent and emerging diseases of animals. IAH Pirbright provided key scientific data and working environment for scientists in a high- This is particularly important now as advice to the Government during the 2001 containment laboratory. An artist’s impression vector-borne diseases are spreading and 2007 FMD outbreaks, the 2007 incursion of the new laboratory is shown below. The new northwards as a consequence of the of bluetongue virus and worked with DEFRA laboratory will house all IAH scientists in a changing climate. and the National Farmers Union to ensure that single envelope containment facility and the IAH already attracts and trains the the UK remained free from bluetongue in 2008 new investment in state-of-the-art facilities for best scientific talent in livestock and 2009. IAH-Pirbright is a unique laboratory IAH will ensure the UK remains in position research across the globe and in the UK due to the portfolio of pathogens to control, contain and eradicate the threats studied and the availability of specialist of established and emerging diseases of provision of the new laboratory will high-containment facilities, both research animals. This national capability is becoming ensure this remains the case. laboratories and large-animal accommodation, increasingly important as vector-borne diseases Research that contributes to the which cannot easily be replicated elsewhere. are spreading northwards as a consequence of development of innovative vaccines Following the 2001 Foot and Mouth climate change and global warming and posing is integral to the work of IAH and outbreak, the various post-outbreak inquiries greater threats to food supply and food security. will long be a central pillar for and reviews concluded there was an urgent Research at the new Pirbright laboratory will better containment, control and need for a major redevelopment of the also focus on combating diseases that spread eradication of many infectious laboratories and facilities at IAH-Pirbright from animals to humans, such as the influenzas.
Load more

Recommended publications
  • TB Vaccine Development
    Impact Objectives • Work towards developing an effective vaccine against tuberculosis (TB) • Confirm the safety and immunogenicity of delivering the MVA85A vaccine by aerosol direct to the respiratory mucosa • Ultimately produce an effective, safe and accessible vaccine for the global prevention of TB Overcoming the challenges of tuberculosis (TB) vaccine development Clinician and Professor of Vaccinology at the University of Oxford in the UK, Helen McShane is using her 26 years of expertise to lead a research team in their quest to develop, assess and apply a new TB vaccine Could you give Could you expand on your own previous significantly less immunogenic in South a brief overview work into the effectiveness of the BCG African infants than it had been in UK adults. of TB in terms vaccination and the work you have led of prevalence developing a booster vaccine? Despite these results, we have learnt a huge of the disease amount from the conduct of this trial, and today, current In 2002, we started a clinical trial programme nine additional papers have been published treatments and with MVA85A, the first subunit vaccine from the data arising from this trial. We their effectiveness, and any drawbacks? candidate TB vaccine to be tested in clinical have gained important insights into immune trials. This vaccine was designed to boost the correlates of risk of TB disease from samples Tuberculosis kills more people today than any effects of BCG. After a careful programme of taken during this trial, how to diagnose other infectious pathogen. The emergence trials in the UK, including testing this vaccine TB in infants, and the role of Quantiferon of multi and extensively drug-resistant in M tb latently infected people, we then testing in infants exposed to TB.
    [Show full text]
  • Hepcidin Deficiency and Iron Deficiency Do Not Alter Tuberculosis Susceptibility in a Murine M
    RESEARCH ARTICLE Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M. tb infection model Rachel Harrington-Kandt1, Elena Stylianou1, Lucy A. Eddowes2, Pei Jin Lim2, Lisa Stockdale3, Nawamin Pinpathomrat1, Naomi Bull1, Janet Pasricha1, Marta Ulaszewska1, Yulia Beglov4, Sophie Vaulont5, Hal Drakesmith2☯*, Helen McShane1☯* a1111111111 1 Jenner Institute, University of Oxford, Oxford, United Kingdom, 2 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 3 Department of a1111111111 Immunology and Infection, London School of Hygiene & Tropical Medicine, London, United Kingdom, a1111111111 4 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 5 Institut a1111111111 Cochin, INSERM 567, CNRS 8104, Universite Paris 5, Paris, France a1111111111 ☯ These authors contributed equally to this work. * [email protected] (HD); [email protected] (HMcS) OPEN ACCESS Abstract Citation: Harrington-Kandt R, Stylianou E, Eddowes LA, Lim PJ, Stockdale L, Pinpathomrat N, Tuberculosis (TB), caused by the macrophage-tropic pathogen Mycobacterium tuberculosis et al. (2018) Hepcidin deficiency and iron (M.tb) is a highly prevalent infectious disease. Since an immune correlate of protection deficiency do not alter tuberculosis susceptibility in or effective vaccine have yet to be found, continued research into host-pathogen interac- a murine M.tb infection model. PLoS ONE 13(1): tions is important. Previous literature reports links between host iron status and disease e0191038. https://doi.org/10.1371/journal. pone.0191038 outcome for many infections, including TB. For some extracellular bacteria, the iron regula- tory hormone hepcidin is essential for protection against infection.
    [Show full text]
  • University of Oxford
    From: Volunteer Recruitment Coordinator Prof Helen McShane FRCP PhD [email protected] FMedSci Chief Investigator, TB Vaccine Trials Jenner Institute, University of Oxford Volunteer Information Sheet Studies of TB vaccines in healthy adults “A human challenge study to evaluate innate and adaptive immune responses to a controlled human infection with BCG administered by the intradermal or aerosol inhaled route in healthy, BCG-naïve, UK adult volunteers” (TB043) Dear volunteer, Thank you for showing interest in this study. Before you decide if you would like to take part, it is important for you to understand why the research is being done and what it would involve. Please take time to read the following information sheet carefully and discuss it with friends, relatives and your GP (General Practitioner) if you wish. Part 1 tells you the purpose of this study and what will happen to you if you take part. Part 2 gives you more details about how this study will be conducted A further information sheet entitled “COVID-19 additional information” will be provided to accompany this information sheet during the COVID-19 pandemic. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether you wish to take part. Volunteer Recruitment Coordinator [email protected] Part 1 What is the purpose of this study? Tuberculosis (also known as TB) is a disease caused by a bacterium (Mycobacterium tuberculosis) that is responsible for more deaths worldwide than any other infectious disease. BCG (Bacille Calmette-Guérin) is the only vaccine currently in use against TB, but it is not always protective.
    [Show full text]
  • Isis Insights 63
    The research commercialisation office of the University of Oxford, previously called Isis Innovation, has been renamed Oxford University Innovation All documents and other materials will be updated accordingly. In the meantime the remaining content of this Isis Innovation document is still valid. URLs beginning www.isis-innovation.com/... are automatically redirected to our new domain, www.innovation.ox.ac.uk/... Phone numbers and email addresses for individual members of staff are unchanged Email : [email protected] Ii 63 Spring 11 Issue Isis insights The latest innovations, collaborations and technology transfer Healthy futures Screening for discovery... IiContents Issue 63 Healthy futures Screening for discovery... Tackling Tuberculosis 10 Protein Superglue 26 Patient Reported Outcomes 28 03. Newsflash 18. Transformers The latest news from Isis Lightweight motor magnets 04. The Loop 20. Testing, Testing A news roundup from Oxford University Making test tube research more reliable Consulting and Isis Enterprise 22. Spring Clean 05. The Portfolio Showcasing clean-tech energy systems Investment and spin-out news 24. Fluid Thinking 06. Technology Steps Forward An acoustic separator for a wide audience The latest licence agreements 26. Protein Superglue Identifying proteins linked with diseases 08. Scouting for Success Oxford Innovation Society member Dow Chemical’s investment strategies 28. The PROs of Academic Consultancy Oxford University Consulting helping with 10. Tackling Tuberculosis healthcare A vaccine for the 21st Century 30. Above Sea Level 12. Oxford-Emergent Tuberculosis Isis Enterprise using submarine technology for Consortium Focus health screening Deeper insight into the TB vaccine partnership 16. Inside the Incubator A new initiative for Oxford software Ii is produced by Isis Innovation Ltd, the technology transfer company owned by the University of Oxford.
    [Show full text]
  • Progress and Challenges in TB Vaccine Development[Version 1
    F1000Research 2018, 7:199 Last updated: 21 MAR 2018 REVIEW Progress and challenges in TB vaccine development [version 1; referees: 2 approved] Gerald Voss1, Danilo Casimiro2,3, Olivier Neyrolles4, Ann Williams5, Stefan H.E. Kaufmann6, Helen McShane7, Mark Hatherill8, Helen A Fletcher 9 1Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands 2Aeras Global TB Vaccine Foundation, Rockville, MD, 20850, USA 3Sanofi Pasteur, Swiftwater, PA, 18370, USA 4Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, Toulouse, France 5Centre for Emergency Preparedness and Response, Public Health England, Salisbury, UK 6Max Planck Institute for Infection Biology, Berlin, Germany 7The Jenner Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK 8South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa 9London School of Hygiene & Tropical Medicine, Immunology & Infection, TB Centre, London, UK v1 First published: 16 Feb 2018, 7:199 (doi: 10.12688/f1000research.13588.1) Open Peer Review Latest published: 16 Feb 2018, 7:199 (doi: 10.12688/f1000research.13588.1) Referee Status: Abstract The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that Invited Referees vaccine mediated protection against TB is a possibility. A new TB vaccine is, 1 2 therefore, an inevitability; the question is how long will it take us to get there? We have made substantial progress in the development of vaccine platforms, in version 1 the identification of antigens and of immune correlates of risk of TB disease.
    [Show full text]
  • Natural History of TB
    ROLE OF CD8 IN PROGRESSION FROM LATENT TO ACTIVE TB Disclosures • David Lewinsohn: • OHSU inventor, CD8+ T cell vaccines and diagnostics • Viti Inc., CEO, current • Spouse Deborah Lewinsohn: • OHSU inventor, CD8+ T cell vaccines and diagnostics • ViTi Inc., President, current • OHSU and Drs. Deborah and David Lewinsohn have a financial interest in ViTi, a company that may have a commercial interest in the results of this research. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU. Using the Host Response to Discern Bacterial Burden The Big Questions: • Following exposure to Mtb who is at risk for disease? • During the course of TB Treatment, can we predict who is likely to relapse? • Can measuring the host response help us where bacterial burden is low? Spectrum of Infection with Mtb CD4+ cells CD8+ T cells Adapted from Young DB et al., Trends Microbiol 2009 Model of Memory: Possible Outcomes Unique functions of CD8+ T cells • Recognition of MHC Class II negative cells • Preferentially recognize heavily infected cells • Discern bacterial burden Unique functions of CD8+ T cells • Recognition of MHC Class II negative cells • Preferentially recognize heavily infected cells • Discern bacterial burden Lewinsohn DA et al., AJRCCM, 2003 Unique functions of CD8+ T cells • Recognition of MHC Class II negative cells • Preferentially CD4+ recognize heavily cells CD8+ infected cells T cells • Discern bacterial burden Adapted from Young DB et al., Trends Microbiol 2009 CD8+ T cells: A reflection
    [Show full text]
  • BCG: What Have We Learnt in 100 Years?
    BCG: What have we learnt in 100 years? Helen McShane The Jenner Institute University of Oxford What we thought we knew? • Safe • Reliable protection against disseminated disease • No effect of boosting on protection against disease • Protection against leprosy • Association with reduction in all cause mortality • Intravesical installation for bladder cancer Pooled rate ratios for pulmonary tuberculosis, according to trial characteristics. Mangtani et al, CID 2013 The magnitude of the BCG-attributable increase in IFNγ correlates with known protective efficacy Malawi UK Black et al, The Lancet 2002 Protection against M.tb infection as determined by QuantiFERON in children vaccinated with BCG. ~15% protection Roy et al, BMJ 2014 What do we now know? • Less safe in some populations (Hessling) • Protection can be durable (Abubakar) BCG IFN-g ELISPOT and Ag85A IgG are immune correlates in BCG-vaccinated infants BCG-IFN- ELISPOT 400 300 OR 0.502, p = 0.013 C M B 200 P n o i l l 150 i m / C 100 F S 50 0 Ag85A IgG Day 0 Ag85A IgG Day 28 4 4 3 3 D D 2 2 O O Fletcher HA et al Nature 1 1 Communications, 2016 0 0 estimated odds ratio 0.62, p = 0.019 BCG revaccination reduces rate of sustained QFT conversion in South African adolescents Nemes et al, NEJM 2018 BCG revaccination in school children in Brazil does not enhance protection against TB disease Rodrigues et al Lancet 2005 “ No evidence that any of the trial vaccines contributed to protection against tuberculosis” Lancet 1996 Why the difference? • Different endpoint • Different population • Difference
    [Show full text]
  • Unique Document Identifier and Title
    CLINICAL TRIAL PROTOCOL A human challenge study to evaluate innate and adaptive immune responses to a controlled human infection with BCG administered by the aerosol inhaled route in healthy, BCG-naïve, UK adult volunteers Short title: Investigating immune responses to aerosol BCG challenge in healthy UK adults Trial Reference: TB043 REC Reference: 18/SC/0307 IRAS Reference: 246087 Date and Version Number 15 January 2019, v2.0 Chief Investigator: Professor Helen McShane Sponsor: University of Oxford Safety Monitoring Committee: Dr Hassan Mahomed Professor Stephen Gordon Dr Francesca Little Funding body: The Wellcome Trust Author: Dr Julia Marshall and Dr Rebecca Powell Doherty Confidentiality Statement This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, and members of the Research Ethics Committee, unless authorised to do so. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Professor Helen McShane. TB043 Clinical Study Protocol v2.0 draft, 15 January 2019, ©University of Oxford CONFIDENTIAL Page 1 of 49 TABLE OF CONTENTS 1 STATEMENT OF COMPLIANCE ............................................................................ 5 2 AMENDMENT HISTORY ...................................................................................... 6 3 KEY STUDY CONTACTS AND ROLES ..................................................................... 7 4 SYNOPSIS .........................................................................................................
    [Show full text]
  • Clinical Development of New TB Vaccines: Recent Advances and Next Steps
    fmicb-10-03154 January 28, 2020 Time: 16:47 # 1 REVIEW published: 30 January 2020 doi: 10.3389/fmicb.2019.03154 Clinical Development of New TB Vaccines: Recent Advances and Next Steps Mark Hatherill1*, Richard G. White2 and Thomas R. Hawn3 1 South African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa, 2 TB Modelling Group, TB Centre – Centre for the Mathematical Modelling of Infectious Diseases, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom, 3 Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, United States Mycobacterium tuberculosis (Mtb) kills more people worldwide than any single infectious pathogen, yet the only vaccine licensed against tuberculosis, Bacille Calmette Guerin (BCG) is approaching its centenary. Two recent advances in clinical tuberculosis vaccine development have invigorated the field. BCG revaccination of interferon-gamma release assay (IGRA) negative adolescents provided 45% protection against sustained Mtb infection defined by IGRA conversion; and the protein-subunit vaccine M72/AS01E provided 50% protection against progression from Mtb infection to tuberculosis disease Edited by: Emilio A. Emini, in IGRA-positive adults. These findings provide encouraging evidence for pre-exposure Bill & Melinda Gates Foundation, and post-exposure approaches to vaccination against tuberculosis, both of which may United States be necessary to rapidly interrupt the cycle of Mtb transmission and sustain long-term Reviewed by: impact on global tuberculosis control. New trials are needed to demonstrate efficacy of Warwick Britton, The University of Sydney, Australia M72/AS01E with greater precision, in a wider age range, in diverse epidemic settings, Helen McShane, and in populations that include Mtb-uninfected and HIV-infected persons.
    [Show full text]
  • Presentation Helen Mcshane
    Helen McShane University of Oxford What is VALIDATE? • Network of researchers working on vaccine R&D for complex intracellular neglected pathogens – Mycobacterium tuberculosis – Mycobacterium leprae – Burkholderia pseudomallei – Leishmania spp • Funded by MRC/BBSRC Global Challenges Research Fund • 36 months in duration • Start date 1st June 2017 VALIDATE Vision - To create an engaged and interactive community of researchers, decision makers and general public - To accelerate vaccine R&D for our focus neglected pathogens - To help Early Career Researcher members progress their careers Cross pathogen Cross species M. tb, Leishmania spp, Mouse, guinea pig, dog, B. pseudomallei, M. leprae cow, NHP, human VALIDATE Cross continent Cross discipline UK, Africa, South East Asia, Basic immunology, clinical, South America social science Image from social sciences.cornell.edu Management Management Team Network Management Board Director Co-Director Network Manager Helen McShane Helen Fletcher Samantha Vermaak Uo Oxford LSHTM Uo Oxford Mitali Chatterjee Andrea Cooper Tracy Hussell Paul Kaye Jomien Mouton Scientific Advisory Board IPGMER Uo Leicester Uo Manchester Uo York Uo Stellenbosch Jo Prior Ann Rawkins Rajko Reljic Rachel Tanner Bernardo Tom Solomon Nicolas Fasel Jelle Thole Dstl PHE SGUL Uo Oxford Villarreal-Ramos Uo Liverpool Uo Lausanne TBVI APHA Network Members Animal Human Clinical & immun • 213 members: human trials -ology 76 Investigators; 63 Associates; 74 Affiliates models • From 105 institutes in 37 countries (24 LMIC) • 62 Academic;
    [Show full text]
  • Safety and Efficacy of MVA85A, a New Tuberculosis Vaccine, in Infants Previously Vaccinated with BCG: a Randomised, Placebo-Controlled Phase 2B Trial
    Articles Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Michele D Tameris*, Mark Hatherill*, Bernard S Landry, Thomas J Scriba, Margaret Ann Snowden, Stephen Lockhart, Jacqueline E Shea, J Bruce McClain, Gregory D Hussey, Willem A Hanekom, Hassan Mahomed†, Helen McShane†, and the MVA85A 020 Trial Study Team Summary Background BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modified Published Online Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective efficacy of BCG. We February 4, 2013 aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis http://dx.doi.org/10.1016/ S0140-6736(13)60177-4 infection in infants. See Online/Comment http://dx.doi.org/10.1016/ Methods In our double-blind, randomised, placebo-controlled phase 2b trial, we enrolled healthy infants S0140-6736(13)60137-3 (aged 4–6 months) without HIV infection who had previously received BCG vaccination. We randomly allocated *Contributed equally infants (1:1), according to an independently generated sequence with block sizes of four, to receive one intradermal †Senior authors dose of MVA85A or an equal volume of Candida skin test antigen as placebo at a clinical facility in a rural region near South African Tuberculosis Cape Town, South Africa. We actively followed up infants every 3 months for up to 37 months. The primary study Vaccine Initiative, Institute of outcome was safety (incidence of adverse and serious adverse events) in all vaccinated participants, but we also Infectious Disease and Molecular Medicine and School assessed efficacy in a protocol-defined group of participants who received at least one dose of allocated vaccine.
    [Show full text]
  • Prot SAP 000.Pdf
    CLINICAL TRIAL PROTOCOL Trial title: Open label, dose escalation and age de-escalation for ChAdOx1 85A in Ugandan adults and adolescents, followed by a Phase IIa randomised, open-label trial among adolescents comparing ChAdOx1 85A prime followed by MVA85A boost versus BCG re- vaccination Short title: EMaBS1 TB Vaccine Study Trial Reference: TB042 UVRI/REC Ref: UNCST Ref: National Drug Authority Ref: LSHTM Ref: OXTREC Ref: 2-18 Date and Version No: 25.08.2017, version 1.1 Chief Investigator: Helen McShane Principal Investigator: Alison Elliott Other Investigators: Anne Wajja, Pontiano Kaleebu Trial Site: Entebbe Hospital and MRC/UVRI Uganda Research Unit on AIDS Sponsor: University of Oxford Funder: Medical Research Council, UK 1 EMABS: Entebbe Mother and Baby Study TB042 Clinical Trial Protocol v1.1 25th August 2017 CONFIDENTIAL Page 1 of 52 Confidentiality Statement This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, host organisation, and members of the Research Ethics Committees and other regulatory bodies. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Professors Helen McShane and Alison Elliott. Statement of Compliance The trial will be conducted in compliance with the protocol, the International Conference on Harmonisation Good Clinical Practice Guideline E6 (R2) (ICH-GCP), Medicines for Human Use (Clinical Trial) Regulations 2004 (as amended) and
    [Show full text]